Ultragenyx receives FDA Breakthrough Therapy Designation for GTX-102 in Angelman syndrome

Ultragenyx Pharmaceutical Inc.

FDA granted Breakthrough Therapy Designation for GTX-102 (apazunersen) for Angelman syndrome.
Based on Phase 1/2 study in 74 patients (4-17 years) with full maternal UBE3A deletion showing consistent developmental gains.
Designation aims to expedite development and review; may enable rolling submission and enhanced FDA guidance.
Positive data shows rapid, sustained improvements across multiple symptom domains over up to three years.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.